Bhaskar Anand - 01 Mar 2023 Form 4 Insider Report for REATA PHARMACEUTICALS INC

Role: SVP, Chief Accounting Officer
Signature: /s/ Tracy Herson, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 01 Mar 2023
Net transactions value: $0
Form type: 4
Filing time: 02 Mar 2023, 16:15:07 UTC
Previous filing: 04 Jan 2023
Next filing: 06 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RETA	Class A common stock	Award	$0	+3,000	+12%	$0.000000	27,750	01 Mar 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RETA	Employee Stock Option (right-to-buy)	Award	$0	+6,000		$0.000000	6,000	01 Mar 2023	Class A common stock	6,000	$28.78	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares represent Restricted Stock Units granted with performance criteria (PSUs). On May 20, 2022, the reporting person was granted 3,000 PSUs. On March 1, 2023, based on the satisfaction of certain performance criteria, the PSUs will vest on March 15, 2023, subject to continued service through the vesting date.
F2	On May 20, 2022, the reporting person was granted an option to purchase 6,000 shares of Class A common stock. On March 1, 2023, based on the satisfaction of certain performance criteria, the options will vest on March 15, 2023, subject to continued service through the vesting date.